Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Saving a million puppies from parvo aim of new multi-year campaignJanuary 15, 2024Elanco has launched the “Defend Puppies. Defeat Parvo.” at VMX 2024, encouraging veterinary professionals to ramp up client education about the deadly disease
Single-dose parvo treatment gets USDA approvalMay 3, 2023Elanco’s Canine Parvovirus Monoclonal Antibody treatment may provide a less intensive solution by targeting the virus with single-dose efficacy in dogs.
Feline diabetes pill gets FDA green lightDecember 9, 2022Bexacat has been approval by the U.S. Food and Drug Administration (FDA) for improved glycemic control in diabetic cats. Developed by Elanco Animal Health, the oral medication, which contains the active ingredient bexagliflozin, marks the first sodium-glucose cotransporter 2 (SGLT2) inhibitor (i.e. not insulin) approved by FDA in any animal species, the agency reports.
Elanco closes $444M purchase of biopharma co.August 31, 2021Elanco Animal Health has expanded its reach into the veterinary dermatology market with the $444-million acquisition of biopharma company, Kindred Biosciences.
Canine lymphoma drug gets full approvalJuly 20, 2021Elanco’s Tanovea product contains the active ingredient rabacfosadine, an acyclic nucleotide phosphonate that kills rapidly growing tumor cells.
Elanco acquires biopharma co. in $440M dealJune 16, 2021A major player in the global animal health industry has expanded its reach into the veterinary dermatology market with the purchase of a biopharmaceutical company.
Oral flea, tick product for cats launchedMay 4, 2021Veterinarians in the U.S. now have an orally administered option for controlling fleas and ticks in feline patients.
National study to shed light on canine OAMarch 22, 2021Gaining insight into the incidence and prevalence of canine osteoarthritis (OA) is the driving force behind a newly announced partnership.
Indiana to welcome animal co.'s global HQDecember 29, 2020Elanco Animal Health, Inc., has selected a downtown Indianapolis location for its new global headquarters.
